BAK1 and cholangiocarcinoma: TRAIL alone had a small apoptotic effect on KMCH cells that was efficiently blocked by Bax/Bak silencing, indicating that TRAIL normally kills cholangiocarcinoma cells by the Type II pathway (Fig. 4D).